Sosei Heptares
Tokyo, JapanWebsite
A science-led biopharmaceutical group focused on the discovery and development of new medicines originating from its proprietary GPCR-targeted structure-based drug design technology.
Loading company information...
A science-led biopharmaceutical group focused on the discovery and development of new medicines originating from its proprietary GPCR-targeted structure-based drug design technology.
Company context
Sosei Heptares prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
Nxera Pharma, formerly known as Sosei Heptares, is a global, fully integrated biopharmaceutical company headquartered in Tokyo, Japan. The company specializes in the discovery and development of novel medicines, with a primary focus on G protein-coupled receptors (GPCRs). By leveraging its proprietary StaR technology and structure-based drug design platform, the company addresses significant unmet medical needs in areas such as neurology, immunology, and gastroenterology. Following the 2015 acquisition of Heptares Therapeutics, the organization has evolved into a powerhouse of scientific innovation with a robust international presence spanning the UK, Japan, Switzerland, and South Korea. In recent years, the company has undergone a strategic transformation to become a fully integrated commercial entity. This includes the acquisition of Idorsia’s business units in Japan and South Korea and the successful launch of commercial therapies like PIVLAZ. Through its rebranding to Nxera Pharma in 2024, the company aims to reflect its expanded capabilities and its commitment to delivering transformative medicines to patients worldwide while maintaining its reputation as a leader in GPCR-targeted drug discovery.
Mission: To discover, develop, and commercialize transformative medicines grounded in top-tier scientific research to improve the lives of patients worldwide. Vision: To become one of Japan’s leading global biopharmaceutical entities.
Founded
1990
Headquarters
Tokyo, Japan
Employees
200-500
Industry
Biotechnology
Cutting-edge scientific environment with access to world-class GPCR research
Strong collaborative culture with global pharmaceutical partners
Opportunity to work on high-impact, life-changing therapeutic assets
High pressure associated with the fast-paced nature of drug discovery
Revenue
Approx. $100M - $200M USD
Funding
Publicly traded on the Tokyo Stock Exchange (Prime Market)
CEO
Shinichi Tamura
Complexity of managing operations across multiple international time zones